Your peers prefer the NovaSure procedure
VIEW IN BROWSER
Hologic
YOUR PEERS HAVE SPOKEN
A recent survey
shows that the
NovaSure
procedure
is
preferred!
device-controller
Survey Shows*
line1
57-percent
who tried the Minerva procedure have discontinued their use of the product
and returned to another ablation device
87-percent
who discontinued their use returned to
the market leader the NovaSure procedure
line2
Continue to choose the market leader that consistently delivers proven outcomes and has been your trusted partner for over 15 years
CHOOSE NOVASURE
line2
*In a random, blind survey of n716 OB/GYNs between June 2016 and October 2017, 121 reported trialing the Minerva device, of which 69 reported discontinuing use and 60 reported switching to the NovaSure device following Minerva trial.
IMPORTANT SAFETY INFORMATION
NovaSure endometrial ablation is for premenopausal women with heavy periods due to benign causes who are finished childbearing. Pregnancy following the NovaSure procedure can be dangerous. The NovaSure procedure is not for those who have or suspect uterine cancer; have an active genital, urinary or pelvic infection; or an IUD. NovaSure endometrial ablation is not a sterilization procedure. Rare but serious risks include, but are not limited to, thermal injury, perforation and infection. Temporary side effects may include cramping, nausea, vomiting, discharge and spotting. Inform patients to contact you if they experience a possible side effect related to use of this product. For detailed benefit and risk information, please consult the IFU.
Hologic, NovaSure, The Science of Sure, and associated logos are trademarks or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. All other trademarks, registered trademarks, and product names are the property of their respective owners.
EMB-01108-001 ©2018 Hologic, Inc.
This email was sent by: Hologic, Inc. 250 Campus Drive, Marlborough, MA 01752